The FDA has granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with hepatocellular carcinoma who have previously received sorafenib.
Liver, Gallbladder, and Biliary Tract Cancers
Lenvatinib demonstrated noninferiority to sorafenib with regard to overall survival in patients with previously untreated, unresectable hepatocellular carcinoma.
The addition of adjuvant oral chemotherapy with capecitabine extended the overall survival of patients with biliary cancers by a median of 15 months, according to the results of the BILCAP study.
The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib.
Interim data from CheckMate 040 showed that nivolumab produces durable responses with promising long-term survival rates in patients with advanced, unresectable hepatocellular carcinoma.
Young men who are overweight or obese are at risk of developing severe liver disease or liver cancer in later life, particularly those who have type 2 diabetes mellitus.
Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial.
Use of stereotactic body radiation therapy (SBRT) was equally effective as transarterial chemoembolization (TACE) as a method of bridge to transplant among patients with hepatocellular carcinoma.
This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib.
A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.